Search PubMed⌕ Search

Biomedical subjects

C A Sinaniotis

Publications and source records attributed to C A Sinaniotis.

13 recordsLinked to original sources
PubMed2004

Viral pneumoniae in children: incidence and aetiology.

Community-acquired pneumonia remains a common and serious illness, which affects children of all age groups. The spectrum of causative organisms is wide and it differs according to the age of the patients. With the advent of new and improved diagnostic techniques our understanding of the aetiology of the disease has been improved considerably. Viruses have been shown to cause up to 90% of pneumonias, especially in the first year of life, with the respiratory syncytial virus to be the most important pathogen and this percentage decreases to approximately 50% by school age. Viral pneumonias frequently are complicated by bacterial infections and mixed infections are identified in 30% of the cases. The precise role of viruses and bacteria in these cases, remains to be clarified.

Child↗
PubMed1999

Community-acquired pneumonia: diagnosis and treatment.

Community-acquired pneumonia remains a common and serious illness, which affects children of all age groups. The spectrum of causative organisms is wide and it differs according to the age of patients. Therefore, age is a good predictor of the cause of pneumonia. Because of the nonspecificity, of clinical and radiological findings and the limitations of diagnostic tests for identifying the etiologic pathogen, initial therapy is inevitably empiric.

Adolescent↗
PubMed1998

Epidemiology of invasive Haemophilus influenzae type b infections among children in Greece before the introduction of immunization.

We prospectively examined the epidemiology of invasive Haemophilus influenzae type b (Hib) infections among children under 5 y of age in the Greater Athens area before the introduction of immunization. The annual incidence of systemic Hib infections was 12/100000. Meningitis was the most common clinical entity and accounted for 69% of the cases. In the prevaccine era, the incidence of systemic Hib disease, particularly that of meningitis, was much lower in Greece compared to rates reported from Northern and Central Europe.

Bacteremia↗
PubMed1981

Clinical pharmacology of cefotaxime in pediatric patients.

Cefotaxime is a new cephalosporin with a spectrum of activity which may make it appropriate for use in pediatric patients. In 33 infants and children, administration of cefotaxime resulted in cure or improvement in 97% of patients, with eradication of 94% of isolated pathogens. Toxicity was minimal. The disposition of cefotaxime in this age group was similar to that reported for adults, with an elimination half-life of approximately 1.5 h, a volume of distribution of 1 liter/kg, a total serum clearance of 10 ml/min per kg, and a renal clearance of 6 ml/min per kg.

Bacterial Infections↗
PubMed1979

Pharmacokinetics of amikacin in infants and pre-school children.

The pharmacokinetic properties of amikacin sulfate in infants and children aged from three weeks to 6 years were studied during treatment with doses of 7.5 mg/kg every 12 hours using standard assay methods and technique of two compartment open model kinetic analysis. Peak serum concentrations of amikacin were measured 30 or 60 min after the first intramuscular injection. These ranged from 11.8 microgram/ml to 23 microgram/ml in infants and from 9.0 microgram/ml to 29 microgram/ml in children. Five minutes after the first intravenous bolous injection they varied from 16 microgram/ml to 29.8 microgram/ml in infants and from 34 microgram/ml to 42 microgram/ml in children. Twelve hours after injection serum concentrations were less than 0.8 microgram/ml in all patients. Mean serum half-lives of amikacin in infants and children were 2.1 hours and 2.0 hours after intramuscular, and 2.2 and 2.0 hours after intravenous administration respectively. No evidence of accumulation was observed after four days treatment. The amount of antibiotic recovered within 12 hours from the urine in all patients ranged from 34.5 to 65% of an intramuscular dose, and from 45.8 to 63.3% of an intravenous dose. The dosage regime of 7.5 mg/kg body weight given every 12 hours should be safe and effective for the treatment of infections in the age groups studied.

Age Factors↗